Close
Find your Coloplast country website
RSS
Need to always be updated?
Sign up to our RSS feed

News and press

Select category

    • News
    9 Oct 2006

    SenSura

    With its newly developed ostomy platform – SenSura – Coloplast once again sets the standard for innovative stoma care products worldwide.

    Read news story

    With its newly developed ostomy platform - SenSura - Coloplast once again sets the standard for innovative stoma care products worldwide.

    The new platform offers highly improved features in the areas of greatest importance to people living with a stoma. SenSura was developed in close collaboration with users and more than 400 stoma care nurses internationally. As of today, the product will be launched in Denmark, and within the next 12 months SenSura will become available in all main markets.

    SenSura achieved an overall user preference of 79-85 percent in clinical studies conducted against leading competitive products. With SenSura users felt more secure due to fewer incidents of leakage, and they felt more comfortable because the new adhesive was more pleasant and gentle on the skin. All of which are highly important factors when it comes to living with a stoma.

    The SenSura double-layer adhesive combines the important adhesive capabilities, which ensure its overall superior performance, compared to today's single layer adhesive products.

    The importance of continuously improving the quality of life for ostomy users was underlined by an international study presented recently at the World Council of Enterostomal Therapists (WCET) in Hong Kong. The OstomySkinStudy revealed that almost half the people living with a stoma suffer from skin problems. These problems primarily occur when stool effluents get in contact with the skin. This may happen if the stoma bag is either not fitted properly or the adhesive used is not good enough.

    As a new platform of ostomy bags, SenSura will eventually address the total DKK 9.5 billion world market for ostomy products. Today the Coloplast market share for ostomy products amounts to 28 per cent globally, primarily obtained through sales in Europe.

    "With the global roll out of SenSura we believe we can support providers and users to live a more comfortable life with ostomy," says Nicolai Buhl Andersen, Senior Vice President at Coloplast's Ostomy Division. "And with this launch we believe we can reach our goal of becoming the world's number one ostomy care provider and partner," says Andersen.

    • News
    2 Aug 2006

    Coloplast rejects suspicion on restrictive practices in Italy

    On 25 July 2006 Coloplast was faced with a dawn raid at its sales subsidiary in Bologna, Italy.

    Read news story

    On 25 July 2006 Coloplast was faced with a dawn raid at its sales subsidiary in Bologna, Italy.

    The Italian competition authorities acted on a claim from the local health authorities in Ferrara stating, that the reason why Coloplast did not bid on a tender for local supply of ostomy products in 2003 could be due to restrictive behaviour by the four main providers of ostomy products in Italy.

    Coloplast rejects these allegations.

    At this point Coloplast awaits further documentation in the case and we are fully co-operating with the authorities. As long as the investigation is ongoing, Coloplast cannot comment any further on the matter.

    • News
    5 Jul 2006

    North American headquarters

    St. Paul - Governor Tim Pawlenty announced today that Coloplast will move its North American corporate headquarters to Minnesota beginning this fall.

    Read news story

    St. Paul - Governor Tim Pawlenty announced today that Coloplast will move its North American corporate headquarters to Minnesota beginning this fall.

    Coloplast CEO Sten Scheibye joined Governor Pawlenty and Minneapolis Mayor R.T. Rybak to announce that at least 300 corporate headquarters jobs are planned to move from Marietta, Georgia, to its new corporate campus on West River Road in North Minneapolis. The move - beginning with the first 200 jobs in September - will enable the company to double the size of its facilities to 500,000 square feet for office, research and development and production activities

    "Coloplast is a world leader in the design and manufacture of high quality and innovative health care products and services," Governor Pawlenty said. "Their decision to come to Minnesota is an important and exciting development that underscores, yet again, our commitment to placing Minnesota squarely at the intersection where medical technology and biosciences converge to create a biobusiness revolution."

    The company specializes in urology and continence care, ostomy care, chronic wound care; skin care and breast care products and services. It employs nearly 7,000 people worldwide, including about 90 people at Coloplast Skin Care Products in North Mankato. Coloplast's recent acquisition of Mentor's Urology Division added about 330 employees in Minneapolis, which will provide the foundation for its U.S. operations.

    "With our high quality of life and growing life sciences industry, Minneapolis is a perfect home for Coloplast," Mayor Rybak said. "As the commercial hub of the upper Midwest, Minneapolis will do everything it can to ensure that Coloplast has the workforce and financial support it needs to succeed in North Minneapolis."

    "Once we completed the acquisition of Mentor, the decision to move our North American headquarters to Minneapolis was an easy one," Scheibye said. "It's clear to us that Minnesota's leaders continue to be visionary and aggressive in building upon an already strong global presence in medical technology and the biosciences. We're delighted to be here and make Minnesota our home."

    Ward Einess, Acting Commissioner of the Minnesota Department of Employment and Economic Development (DEED), said the state will provide a forgivable $500,000 Minnesota Investment Fund loan to help with the costs of corporate location. DEED also has offered to provide workforce training opportunities and technical assistance to the company.

    "This is a key biosciences business development expansion for Minnesota, and a real win for our efforts to grow this industry in our state," Einess said.

    Coloplast is now looking into how it further can expand its Minneapolis location. The company expects to begin its headquarters relocation in September and to complete the move into its Minneapolis facility by the end of next year.

    • News
    3 Jul 2006

    Ostomy skin study

    A new study has revealed that almost half of all people living with a permanent stoma have a skin disorder around their stoma that may be avoided by regular visits to a specialist nurse.

    Read news story

    A new study has revealed that almost half of all people living with a permanent stoma have a skin disorder around their stoma that may be avoided by regular visits to a specialist nurse.

    These disorders cause significant discomfort and reduce the quality of life for the affected individual. The results of the study have just been presented at the biennial congress of the World Council of Enterostomal Therapists (WCET) in Hong Kong on 2-6 July 2006.

    The OstomySkinStudy, which studied a diverse group of people with ostomies living in the community, found that 45% of the group had skin disorders around their stoma. Surprisingly, many of these people did not realise they had a skin disorder, and more than 80% had not sought help from their physician or stoma-care nurse. Furthermore, some patients did not recognize their condition even when specialized physicians diagnosed their skin disorder as severe.

    The study was performed by stoma care nurses and physicians in association with Coloplast, a world leading developer and manufacturer of ostomy products.

    Skin disorders are a common problem for patients living with an ostomy. The study also shows that waste getting in contact with the skin as it leaves the stoma is the main cause of skin disorders. Many patients living with a stoma have come to accept the resulting discomfort and impaired quality of life.

    Dr. Gregor Jemec, chairman of the department of Dermatology at Roskilde University Hospital, Denmark who supervised the study says: "This important bench-marking study is based on a representative sample of patients and shows the scope of ostomy care to improve the lives of many patients".
    Stoma-care nurses who examined patients in the OstomySkinStudy have recommended regular, annual follow-up visits for all people living with ostomies at their local stoma care clinic.

     

    About ostomy

    An ostomy is a surgical procedure that creates an artificial opening in the body, called a stoma (from the Greek word for ‘mouth'). The stoma provides an alternative way to get rid of waste when the normal route is unable to function due to disease or injury. Waste is collected in a bag that is attached to the skin surrounding the stoma with an adhesive. In the intestinal tract, the opening can be made in the large intestine (colostomy) or the small intestine (ileostomy). In both types of ostomy, waste leaves the body through the stoma instead of through the rectum. A third type of ostomy, a urostomy, allows urine to pass out of the body.

    In Western countries it is estimated that 1 out of 1000 people are living with a stoma.

    • News
    16 Jun 2006

    Coloplast launches new fistula product

    Coloplast's Ostomy Care Division has developed a new type of fistula pouch that can make everyday life easier for patients with fistulas in exuding wounds.

    Read news story

    Coloplast's Ostomy Care Division has developed a new type of fistula pouch that can make everyday life easier for patients with fistulas in exuding wounds.

    For the first time, Coloplast is launching a new type of fistula pouch, Fistula & Wound Management System that can treat fistulas in exuding wounds. Almost 25,000 persons worldwide suffer from fistulas each year. The product will initially be marketed in the USA.

    A fistula is an involuntary passage from the bowel organs out through the stomach that is created by the body. The condition is typically caused by inflammation of the bowel organs (e.g. Morbus Crohn) or radiation damage. The condition may result in the patient developing large exuding wounds around the fistula, resulting in the patient requiring a temporary stoma. At worst, the bowel system may fail, resulting in the patient needing a permanent stoma.

    Coloplast has not previously marketed products of this type. The potential market for fistula pouches corresponds to just under 2% of Coloplast's existing market for ostomy products. The product is sold to hospitals, which use it in their treatment of patients for up to three months at a time.

    The new product has been developed in close collaboration with stoma care nurses, who often treat fistulas in exuding wounds.

    • News
    28 Mar 2006

    World premiere from Coloplast

    The world's first wound dressing with built-in pain medication.

    Read news story

    The world's first wound dressing with built-in pain medication

    A medical breakthrough in the form of a dressing with built-in pain medication was launched today at London's Royal College of Physicians. As the world's first, the new type of dressing is able to reduce ongoing pain for people with chronic wounds, by delivering ibuprofen directly into the wound. Painful wounds that will not heal such as leg ulcers and pressure sores are a common but overlooked problem. With more than 10 million people in Europe affected during a lifetime, chronic wounds are almost twice as common as rheumatoid arthritis.

    The new pain-reducing dressing called Biatain - Ibu was developed by Danish medical device manufacturer Coloplast. Precisely engineered but ingeniously simple, it absorbs and evaporates away large quantities of wound fluid. At the same time it slowly and constantly delivers low-dosage ibuprofen, one of the world's best proven pain-reducing drugs, directly into the wound, bypassing common side affects of oral pain-reducing drugs.

    The dosage of ibuprofen in the pain-reducing dressing equals a quarter of a tablet. Clinical studies show a significant reduction of pain within a few hours after the dressing is applied. The sustained pain reducing effect of the dressing will last for up to 7 days. According to one study, patients were happier and more relaxed with the new kind of dressing, simply because they suffered less from ongoing pain.

    A chronic wound is defined as a wound that does not heal within three months, but some people can have wounds that take years to heal. During this time the pain for many sufferers is almost unbearable and can lead to insomnia, reduced physical activity, isolation and depression.

    Stephen Strang from Canada, a 61-years old executive, has had problems with wounds that will not heal for about a year. He was amazed at the amount of painkillers he took and would still be in pain. As a consequence he got drowsy and was worried that continued medication could cause problems for him. Biatain - Ibu has changed all that. "By the time I reached the door to leave the doctor's office, I had no pain," he says.

    "This is a real breakthrough for countless people who are suffering needlessly from these wounds", says C. Richard Chapman, professor and director of the Pain Research Center at the University of Utah. A world known expert on pain, he urges the medical community at large to focus more attention on the suffering caused by chronic wounds.

    Lesley Thorne, a British Tissue Viability Nurse at the Manchester Royal Infirmary describes the daily reality for chronic wound sufferers: "It is terrible for these patients. They are in such constant pain and agony and it doesn't matter what is done, it doesn't get any better."

    Christine Moffatt, who is Professor of Nursing at Thames Valley University, London, and Director of the Centre for Research and Implementation of Clinical Practice, says: "The traditional tablets that patients take for pain simply don't help. It seems that this particular product is able to apply the actual pain-relieving agent to the area of the wound. It gets to the source of where the pain is and switches it off in the wound itself, and this seems to be very beneficial."

    With the new pain-reducing dressing, Coloplast continues its tradition for developing medical devices and services that contribute to a better quality of life for the users.

    The global market for moist wound healing amounts to approximately €1.9 billion per year.

    The event today in London included speeches from world leading pain expert, Professor C. Richard Chapman, Mandy Leighton-Bellichach, President of the European Pain Network and Chairperson of the Society for Fighting Pain in Israel and Madeleine Flanagan, Principal Lecturer, Tissue Viability, University of Hertfordshire (see background information).

    International Coloplast spokespeople:
    Tina Hahn, Dr., International Medical Outcome Manager
    Marie-Louise Haxthausen, International Brand Manager

    View desktop version

    You are about to leave the Coloplast website.

    Continue on the website ({url})